Clinical Research Directory
Browse clinical research sites, groups, and studies.
HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications
Sponsor: Helsinki University Central Hospital
Summary
Pancreatic resections carry a high risk for complications, especially pancreatic fistula. Both hydrocortisone and pasireotide have been shown to be effective in reducing complications in earlier RCTs. The aim of this study is to compare the effectiveness and safety of these two drugs in preventing complications of pancreatic surgery.
Official title: HYPAR Trial - Hydrocortisone vs Pasireotide in Reducing Pancreatic Fistula and Other Complications After Pancreatic Resection - a Prospective, Randomized, Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
126
Start Date
2016-05
Completion Date
2029-12
Last Updated
2020-08-24
Healthy Volunteers
No
Conditions
Interventions
Hydrocortisone
Pasireotide
Locations (1)
Helsinki University Central Hospital
Helsinki, Finland